SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cyclacel Pharmaceuticals, Inc.'s Novel Polo-Like Kinase 1 (Plk1) Inhibitors Highlighted at American Association for Cancer Research